Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer - Monk, B. J.; Herzog, T. J.; Kaye, S. B.; Krasner, C. N.; Vermorken, J. B.; Muggia, F.; Pujade-Lourraine, E.; Zintl, P.; Parekh, T. V.; Poveda, A. (Journal of clinical oncology, 2011)